Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer.

What Researchers Did

Researchers retrospectively evaluated the efficacy and tolerability of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy in 44 patients with stage IV non-small cell lung cancer.

What They Found

The overall response rate was 61.4%, with 15.9% of patients achieving stable disease. The mean overall survival was 42.9 months (95% CI: 34.0-51.8), and mean progression-free survival was 41.0 months (95% CI: 31.1-50.9). The combination therapy was well-tolerated, with acceptable toxicity and no significant problems related to the adjunctive therapies.

Canadian Relevance

This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or patients.

Study Limitations

A key limitation of this study is its retrospective design, which can be prone to selection bias and confounding factors.